FS 3D CONCORD
MF C22 H23 N5 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> log y
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	22.80	23.01

STN INTERNATIONAL LOGOFF AT 12:36:43 ON 02 AUG 2004

```
=> log y
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY     SESSION
FULL ESTIMATED COST                                        23.61       23.82

STN INTERNATIONAL LOGOFF AT 08:02:35 ON 02 AUG 2004

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:41:10 ON 02 AUG 2004

=> fil uspatfull
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY     SESSION
FULL ESTIMATED COST                                         0.21        0.21

FILE 'USPATFULL' ENTERED AT 08:41:22 ON 02 AUG 2004

=> s 2002:280635/an and 330786-44-2
             1 2002:280635/AN
             0 330786-44-2
L1           0 2002:280635/AN AND 330786-44-2

=> s 2002:280635/an and 330786-44-2/rn
             1 2002:280635/AN
             2 330786-44-2/RN
L2           1 2002:280635/AN AND 330786-44-2/RN

=> d hitrn

L3   ANSWER 1 OF 1  USPATFULL on STN
IT   330786-44-2P, trans-Benzyl N-[4-[4-amino-1-[4-(4-
     methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-
     methoxyphenyl]carbamate
       (intermediate; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines
       as protein kinase inhibitors with antiangiogenic properties)


=> fil reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY     SESSION
FULL ESTIMATED COST                                         4.35       20.76

FILE 'REGISTRY' ENTERED AT 08:49:47 ON 02 AUG 2004

=> s (330786-44-2 or 330786-46-4 or 330787-02-5 or 330789-32-7 or 330791-29-2 or
330791-36-1 or 330791-47-4)/rn
             1 330786-44-2/RN
             1 330786-46-4/RN
             1 330787-02-5/RN
             1 330789-32-7/RN
             1 330791-29-2/RN
             1 330791-36-1/RN
             1 330791-47-4/RN
L4           7 (330786-44-2 OR 330786-46-4 OR 330787-02-5 OR 330789-32-7 OR
               330791-29-2 OR 330791-36-1 OR 330791-47-4)/RN

=> d tot

L4   ANSWER 1 OF 7  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   330791-47-4  REGISTRY
```

CN 2-Benzofurancarboxamide, N-[4-[4-amino-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamide

FS STEREOSEARCH

MF C32 H36 N8 O3

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN

RN **330791-36-1** REGISTRY

CN Benzenepropanamide, N-[4-[4-amino-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-β,β-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methyl-3-phenylbutanamide
FS STEREOSEARCH
MF C34 H44 N8 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN **330791-29-2** REGISTRY
CN Benzenepropanamide, N-[4-[4-amino-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide
FS STEREOSEARCH
MF C34 H44 N8 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN **330789-32-7** REGISTRY
CN Benzenepropanamide, N-[4-[4-amino-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide
FS STEREOSEARCH
MF C32 H40 N8 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN **330787-02-5** REGISTRY
CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[3-methoxy-4-[(phenylmethyl)amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Trans-3-[4-(Benzylamino)-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine
FS STEREOSEARCH
MF C30 H38 N8 O
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: RACT (Reactant or reagent)
RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN **330786-46-4** REGISTRY
CN Benzamide, N-[4-[4-amino-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzamide
FS STEREOSEARCH
MF C30 H36 N8 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN **330786-44-2** REGISTRY
CN Carbamic acid, [4-[4-amino-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN trans-Benzyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate
FS STEREOSEARCH
MF C31 H38 N8 O3
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> fil uspatfull
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      14.49      35.25

FILE 'USPATFULL' ENTERED AT 08:52:50 ON 02 AUG 2004


=> s (330786-44-2 or 330786-46-4 or 330787-02-5 or 330789-32-7 or 330791-29-2 or
330791-36-1 or 330791-47-4)/rn and 2002:280635/an
             2 330786-44-2/RN
             2 330786-46-4/RN
             1 330787-02-5/RN
             3 330789-32-7/RN
             2 330791-29-2/RN
             2 330791-36-1/RN
             2 330791-47-4/RN
             1 2002:280635/AN
L5           1 (330786-44-2 OR 330786-46-4 OR 330787-02-5 OR 330789-32-7 OR
               330791-29-2 OR 330791-36-1 OR 330791-47-4)/RN AND 2002:280635/AN

=> d hitrn

L5   ANSWER 1 OF 1  USPATFULL on STN
IT   330786-44-2P, trans-Benzyl N-[4-[4-amino-1-[4-(4-
      methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-
      methoxyphenyl]carbamate 330786-46-4P, trans-N-[4-[4-Amino-1-[4-
      (4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-
      methoxyphenyl]benzamide 330791-29-2P, trans-N-[4-[4-Amino-1-[4-
      (4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-
      methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide 330791-36-1P,
      trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-
```

d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methyl-3-phenylbutanamide
330791-47-4P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamide
(intermediate; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT **330787-02-5**, Trans-3-[4-(Benzylamino)-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine
(preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT **330789-32-7P**, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide
(protein kinase inhibitor; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

```
=> log y
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       3.00      38.25

STN INTERNATIONAL LOGOFF AT 08:53:59 ON 02 AUG 2004

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:10:35 ON 02 AUG 2004

=> fil hcapl
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'HCAPLUS' ENTERED AT 11:11:13 ON 02 AUG 2004

=> s calderwood?/au and 2000/py
          570 CALDERWOOD?/AU
      1015953 2000/PY
L1          30 CALDERWOOD?/AU AND 2000/PY

=> s l1 and rafferty?/au
          705 RAFFERTY?/AU
L2          6 L1 AND RAFFERTY?/AU

=> d tot

L2   ANSWER 1 OF 6  HCAPLUS  COPYRIGHT 2004 ACS on STN
TI   Preparation of pyrrolopyrimidines as tyrosine kinase inhibitors
SO   U.S. Pat. Appl. Publ., 166 pp., Cont.-in-part of Appl. No. PCT/US99/21560.
     CODEN: USXXCO
IN   Hirst, Gavin C.; Calderwood, David; Munschauer, Rainer; Arnold,
     Lee D.; Johnston, David N.; Rafferty, Paul
AN   2003:633320  HCAPLUS
DN   139:180075
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    -------------------      --------
PI   US 2003153752         A1    20030814    US 2000-537167           20000329
     US 6713474            B2    20040330
     WO 2000017203         A1    20000330    WO 1999-US21560          19990917 <--
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
             MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
```

SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

ZA 2001002204	A	20020318	ZA 2001-2204	20010316

L2 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation and effects of benzothiazinones and benzoxazinones as protein kinase inhibitors
SO PCT Int. Appl., 183 pp.
CODEN: PIXXD2
IN **Rafferty, Paul**; **Calderwood, David**; Arnold, Lee D.; Gonzalez Pascual, Beatriz; Ortego Matinez, Jose L.; Perez de Vega, Maria J.; Fernandez, Isabel F.
AN 2000:881149 HCAPLUS
DN 134:42147

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000075139	A2	20001214	WO 2000-US15324	20000602 <--
WO 2000075139	A3	20010329		
W: AU, BG, BR, CA, CN, CZ, HR, HU, ID, IL, IN, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR, UA, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1181282	A2	20020227	EP 2000-936476	20000602
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 2000011063	A	20020416	BR 2000-11063	20000602
JP 2003501429	T2	20030114	JP 2001-502421	20000602
ZA 2001009610	A	20030221	ZA 2001-9610	20011121
NO 2001005899	A	20020130	NO 2001-5899	20011203
BG 106238	A	20020830	BG 2001-106238	20011219

L2 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II
SO Bioorganic & Medicinal Chemistry Letters (**2000**), 10(19), 2171-2174
CODEN: BMCLE8; ISSN: 0960-894X
AU Burchat, A. F.; **Calderwood, D. J.**; Hirst, G. C.; Holman, N. J.; Johnston, D. N.; Munschauer, R.; **Rafferty, P.**; Tometzki, G. B.
AN 2000:656737 HCAPLUS
DN 134:13076

L2 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I
SO Bioorganic & Medicinal Chemistry Letters (**2000**), 10(19), 2167-2170
CODEN: BMCLE8; ISSN: 0960-894X
AU Arnold, L. D.; **Calderwood, D. J.**; Dixon, R. W.; Johnston, D. N.; Kamens, J. S.; Munschauer, R.; **Rafferty, P.**; Ratnofsky, S. E.
AN 2000:656736 HCAPLUS
DN 134:13075

L2 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
IN **Calderwood, David John**; Johnston, David Norman; **Rafferty, Paul**; Twigger, Helen Louise; Munschauer, Rainer; Arnold, Lee
AN 1998:640260 HCAPLUS
DN 129:275922

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9841525	A1	19980924	WO 1998-EP1357	19980309	
	W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	AU 9868293	A1	19981012	AU 1998-68293	19980309	
	EP 970084	A1	20000112	EP 1998-913690	19980309	<--
	EP 970084	B1	20030604			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO					
	BR 9808281	A	20000516	BR 1998-8281	19980309	<--
	NZ 337529	A	20001027	NZ 1998-337529	19980309	<--
	JP 2001516353	T2	20010925	JP 1998-540090	19980309	
	AT 242245	E	20030615	AT 1998-913690	19980309	
	PT 970084	T	20031031	PT 1998-913690	19980309	
	CN 1134438	B	20040114	CN 1998-805152	19980309	
	NO 9904509	A	19990917	NO 1999-4509	19990917	

L2 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Imidazole derivatives as therapeutic agents
SO PCT Int. Appl., 291 pp.
CODEN: PIXXD2
IN **Calderwood, David John**; Fisher, Adrian John; Jeffery, James Edward; Jones, Colin Gerhart Pryce; **Rafferty, Paul**
AN 1995:789136 HCAPLUS
DN 123:198799

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9500493	A1	19950105	WO 1994-EP1924	19940610	
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	AU 9471849	A1	19950117	AU 1994-71849	19940610	
	EP 705251	A1	19960410	EP 1994-920929	19940610	
	R: DE, FR, GB, IT					
	JP 09501650	T2	19970218	JP 1994-502402	19940610	
	ZA 9404422	A	19950206	ZA 1994-4422	19940621	
	US 5780642	A	19980714	US 1997-786960	19970123	
	US 6031109	A	20000229	US 1998-50396	19980331	<--
	US 6215001	B1	20010410	US 1999-415516	19991007	
	US 6326500	B1	20011204	US 2000-748008	20001227	

=> d all 3,4

L2 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:656737 HCAPLUS
DN 134:13076
ED Entered STN: 20 Sep 2000
TI Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II
AU Burchat, A. F.; **Calderwood, D. J.**; Hirst, G. C.; Holman, N. J.; Johnston, D. N.; Munschauer, R.; **Rafferty, P.**; Tometzki, G. B.
CS BASF Bioresearch Corporation, Worcester, MA, 01605-5314, USA
SO Bioorganic & Medicinal Chemistry Letters (**2000**), 10(19), 2171-2174
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English

CC 1-3 (Pharmacology)
Section cross-reference(s): 28

AB Pyrrolo[2,3-d]pyrimidines containing a 5-(4-phenoxyphenyl) substituent are novel, potent and selective inhibitors of lck in vitro. Exploration of C-6 position of the pyrrolo[2,3-d]pyrimidine and the terminal Ph group structure-activity relationship (SAR) is detailed. Compound 1 is orally active in animal models.

ST pyrrolopyrimidine analog src lck inhibiting structure IFNgamma

IT Structure-activity relationship
(enzyme-inhibiting; pyrrolopyrimidines as potent and selective inhibitors of lck II)

IT Drug design
(pyrrolopyrimidines as potent and selective inhibitors of lck II)

IT Interferons
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(γ; pyrrolopyrimidines as potent and selective inhibitors of lck II)

IT 213743-29-4P 213743-30-7P 213743-38-5P 213743-44-3P 213743-46-5P
213743-50-1P 213743-54-5P 213743-66-9P 213744-00-4P 213744-02-6P
213744-06-0P 262430-74-0P 262430-83-1P 262431-15-2P 262431-28-7P
262431-64-1P 262431-65-2P 262433-34-1P 309724-08-1P 309724-09-2P
309724-10-5P 309724-11-6P 309724-12-7P 309724-13-8P 309724-14-9P
309724-15-0P 309724-16-1P
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(pyrrolopyrimidines as potent and selective inhibitors of lck II)

IT 213743-31-8
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(pyrrolopyrimidines as potent and selective inhibitors of lck II)

IT 114051-78-4, Protein tyrosine kinase Lck 137632-06-5, Csk protein tyrosine kinase 140208-17-9, Lyn protein tyrosine kinase 141349-87-3, c-Fyn protein tyrosine kinase 144941-35-5, Protein tyrosine kinase Blk
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(pyrrolopyrimidines as potent and selective inhibitors of lck II)

IT 213744-87-7P
RL: BPR (Biological process); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(pyrrolopyrimidines as potent and selective inhibitors of lck II)

IT 213744-90-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(pyrrolopyrimidines as potent and selective inhibitors of lck II)

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Arnold, L; Bioorg Med Chem Lett 2000, V10, P2167 HCAPLUS
(2) Calderwood, D; 2000 HCAPLUS
(3) Calderwood, D; PCT Int Appl WO 200017202
(4) Hunter, T; Cell 1995, V80, P225 HCAPLUS
(5) Qian, D; Curr Opin Cell Biol 1997, V9, P205 HCAPLUS
(6) Schindler, T; J Mol Cell 1999, V3, P639 HCAPLUS
(7) Sicheri, F; Nature 1997, V385, P602 HCAPLUS
(8) van Oers, N; J Exp Med 1996, V183, P1053 HCAPLUS
(9) Weil, R; Curr Top Microbiol Immunol 1996, V205, P63 HCAPLUS
(10) Xu, W; Nature 1997, V385, P595 HCAPLUS
(11) Yamaguchi, H; Nature 1996, V384, P484 HCAPLUS

(12) Zhu, X; Structure 1999, V7, P651 HCAPLUS

L2 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:656736 HCAPLUS
DN 134:13075
ED Entered STN: 20 Sep 2000
TI Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I
AU Arnold, L. D.; **Calderwood, D. J.**; Dixon, R. W.; Johnston, D. N.; Kamens, J. S.; Munschauer, R.; **Rafferty, P.**; Ratnofsky, S. E.
CS BASF Bioresearch Corporation, Worcester, MA, 01605-5314, USA
SO Bioorganic & Medicinal Chemistry Letters (**2000**), 10(19), 2167-2170
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
CC 1-3 (Pharmacology)
Section cross-reference(s): 28
AB Pyrrolo[2,3-d]pyrimidines containing a 5-(4-phenoxyphenyl) substituent are potent and selective inhibitors of lck in vitro; some compds. are selective for lck over src. Data are shown for two compds. demonstrating that they are potent and selective inhibitors of IL2 production in cells.
ST pyrrolopyrimidine prep structure IL2 src lck inhibiting; crystal structure pyrrolopyrimidine IL2 src lck inhibitor
IT Tyrosine kinase receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Tie, 2; pyrrolopyrimidines as potent and selective inhibitors of lck I)
IT Structure-activity relationship
(enzyme-inhibiting; pyrrolopyrimidines as potent and selective inhibitors of lck I)
IT Crystal structure
(pyrrolopyrimidines as potent and selective inhibitors of lck I)
IT Interleukin 2
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(pyrrolopyrimidines as potent and selective inhibitors of lck I)
IT 172889-26-8P 213743-29-4P 213743-30-7P 213743-31-8P 213743-80-7P 213743-82-9P 309739-66-0P 309739-67-1P 309739-68-2P 309739-69-3P 309739-70-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(pyrrolopyrimidines as potent and selective inhibitors of lck I)
IT 114051-78-4, Protein kinase lck 141349-89-5, Src Protein tyrosine kinase 150977-45-0, Kdr receptor tyrosine kinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(pyrrolopyrimidines as potent and selective inhibitors of lck I)
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Altman, E; PCT Int Appl WO 9728161 1997 HCAPLUS
(2) Calderwood, D; US 6001839 1999 HCAPLUS
(3) Coligan, J; Current Protocols in Immunology 1998
(4) Farley, K; Anal Biochem 1992, V203, P151 HCAPLUS
(5) Furet, P; J Comput-Aided Mol Des 1995, V9, P465 HCAPLUS
(6) Hanke, J; J Biol Chem 1996, V271, P695 HCAPLUS
(7) Qian, D; Curr Opin Cell Biol 1997, V9, P205 HCAPLUS
(8) Schindler, T; J Mol Cell 1999, V3, P639 HCAPLUS
(9) Sicheri, F; Curr Opin Cell Biol 1997, V7, P777 HCAPLUS
(10) Sicheri, F; Nature 1997, V385, P602 HCAPLUS
(11) Traxler, P; Pharmacol Ther 1999, V82, P195 HCAPLUS

(12) Xu, W; Nature 1997, V385, P595 HCAPLUS
(13) Yamaguchi, H; Nature 1996, V384, P484 HCAPLUS
(14) Zhu, X; Structure 1999, V7, P651 HCAPLUS

```
=> fil uspatfull
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                          ENTRY    SESSION
FULL ESTIMATED COST                                       25.06      25.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                          ENTRY    SESSION
CA SUBSCRIBER PRICE                                       -1.47      -1.47

FILE 'USPATFULL' ENTERED AT 11:14:14 ON 02 AUG 2004

=> s 6001839/pn or 2003187001/pn
             0 6001839/PN
             0 2003187001/PN
L3           0 6001839/PN OR 2003187001/PN

=> s calderwood?/in and rafferty?/in
            49 CALDERWOOD?/IN
           170 RAFFERTY?/IN
L4          10 CALDERWOOD?/IN AND RAFFERTY?/IN

=> s l4 and 1999/py
        184102 1999/PY
L5           1 L4 AND 1999/PY

=> d
L5   ANSWER 1 OF 1  USPATFULL on STN
AN     1999:163694  USPATFULL
TI     Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors
IN     Calderwood, David J., Nottingham, United Kingdom
       Johnston, David N., Nottingham, United Kingdom
         Rafferty, Paul, Nottingham, United Kingdom
       Twigger, Helen L., Nottingham, United Kingdom
       Munschauer, Rainer, Shrewsbury, MA, United States
       Arnold, Lee, Westborough, MA, United States
PA     BASF Aktiengesellschaft, Rheinland-Pfalz, Germany, Federal Republic of
       (non-U.S. corporation)
PI     US 6001839              19991214                              <--
AI     US 1998-42702           19980317 (9)
PRAI   US 1997-40836P      19970319 (60)
DT     Utility
FS     Granted
LN.CNT 2239
INCL   INCLM: 514/258.000
       INCLS: 544/280.000
NCL    NCLM:  514/265.100
       NCLS:  544/280.000
IC     [6]
       ICM: C07D487-04
       ICS: A61K031-505
EXF    544/280; 514/258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> s 6001839/pi or 2003187001/pi
'PI' IS NOT A VALID FIELD CODE
             0 6001839/PI
             0 2003187001/PI
```

```
L6            0 6001839/PI OR 2003187001/PI

=> s l4 and 2003/py
         401204 2003/PY
L7            3 L4 AND 2003/PY

=> d tot

L7   ANSWER 1 OF 3  USPATFULL on STN
AN     2003:321522  USPATFULL
TI     Pyrazolopyrimidines as therapeutic agents
IN     Hirst, Gavin C., Marlborough, MA, United States
         Rafferty, Paul, Westborough, MA, United States
       Ritter, Kurt, Newton, MA, United States
         Calderwood, David, Framingham, MA, United States
       Wishart, Neil, Jefferson, MA, United States
       Arnold, Lee D., Westborough, MA, United States
       Friedman, Michael M., Newton, MA, United States
PA     Abbott GmbH & Co. KG, Wiesbaden, GERMANY, FEDERAL REPUBLIC OF (non-U.S.
       corporation)
PI     US 6660744          B1   20031209                                  <--
AI     US 2000-663780           20000915 (9)
PRAI   US 1999-154620P     19990917 (60)
DT     Utility
FS     GRANTED
LN.CNT 17542
INCL   INCLM: 514/258.000
       INCLS: 544/262.000
NCL    NCLM:  514/262.100
       NCLS:  514/210.210; 544/262.000
IC     [7]
       ICM: C07D487-04
       ICS: A61K031-519; A61P003-10; A61P009-10; A61P035-02
EXF    544/262; 514/258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7   ANSWER 2 OF 3  USPATFULL on STN
AN     2003:265984  USPATFULL
TI     4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS
IN     CALDERWOOD, DAVID, FRAMINGHAM, MA, UNITED STATES
       ARNOLD, LEE, WESTBORO, MA, UNITED STATES
       MAZDIYASNI, HORMOZ, DOUGLAS, MA, UNITED STATES
       HIRST, GAVIN C., MARLBORO, MA, UNITED STATES
       DENG, BOJUAN B., SHREWSBURY, MA, UNITED STATES
       JOHNSTON, DAVID N., NOTTINGHAM, ENG, UNITED STATES
         RAFFERTY, PAUL, NOTTINGHAM, ENG, UNITED STATES
       TOMETZKI, GERALD B., NOTTINGHAM, ENG, UNITED STATES
       TWIGGER, HELEN L., NOTTINGHAM, ENG, UNITED STATES
       MUNSCHAUER, RAINER, NEUSTADT, GERMANY, FEDERAL REPUBLIC OF
PI     US 2003187001       A1   20031002                                  <--
AI     US 1999-399083      A1   19990917 (9)
RLI    Continuation-in-part of Ser. No. US 1998-42702, filed on 17 Mar 1998,
       GRANTED, Pat. No. US 6001839
PRAI   US 1998-100954P     19980918 (60)
DT     Utility
FS     APPLICATION
LN.CNT 5686
INCL   INCLM: 514/265.100
       INCLS: 544/280.000
NCL    NCLM:  514/265.100
       NCLS:  544/280.000
IC     [7]
       ICM: A61K031-519
       ICS: C07D487-02
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 3 USPATFULL on STN
AN 2003:220461 USPATFULL
TI Pyrrolopyrimidines as therapeutic agents
IN Hirst, Gavin C., Marlborough, MA, UNITED STATES
Calderwood, David, Framingham, MA, UNITED STATES
Munschauer, Rainer, Neustadt, GERMANY, FEDERAL REPUBLIC OF
Arnold, Lee D., Westborough, MA, UNITED STATES
Johnston, David N., Nottingham, UNITED KINGDOM
Rafferty, Paul, Nottingham, UNITED KINGDOM
PI US 2003153752 A1 20030814 <--
US 6713474 B2 20040330
AI US 2000-537167 A1 20000329 (9)
RLI Continuation-in-part of Ser. No. WO 1999-US21560, filed on 17 Sep 1999, UNKNOWN
PRAI US 1998-100832P 19980918 (60)
US 1998-100833P 19980918 (60)
US 1998-100834P 19980918 (60)
US 1998-100946P 19980918 (60)
DT Utility
FS APPLICATION
LN.CNT 13805
INCL INCLM: 544/117.000
INCLS: 544/280.000; 514/234.200; 514/252.160; 514/265.100
NCL NCLM: 514/218.000
NCLS: 514/228.500; 514/234.200; 514/252.160; 514/252.180; 514/252.190; 514/252.200; 514/265.100; 540/575.000; 544/061.000; 544/117.000; 544/230.000; 544/280.000
IC [7]
ICM: A61K031-5377
ICS: A61K031-496; A61K031-519; C07D487-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l5 or 2003:265984/an
1 2003:265984/AN
L8 2 L5 OR 2003:265984/AN

=> d tot

L8 ANSWER 1 OF 2 USPATFULL on STN
AN **2003:265984** USPATFULL
TI 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS
IN CALDERWOOD, DAVID, FRAMINGHAM, MA, UNITED STATES
ARNOLD, LEE, WESTBORO, MA, UNITED STATES
MAZDIYASNI, HORMOZ, DOUGLAS, MA, UNITED STATES
HIRST, GAVIN C., MARLBORO, MA, UNITED STATES
DENG, BOJUAN B., SHREWSBURY, MA, UNITED STATES
JOHNSTON, DAVID N., NOTTINGHAM, ENG, UNITED STATES
RAFFERTY, PAUL, NOTTINGHAM, ENG, UNITED STATES
TOMETZKI, GERALD B., NOTTINGHAM, ENG, UNITED STATES
TWIGGER, HELEN L., NOTTINGHAM, ENG, UNITED STATES
MUNSCHAUER, RAINER, NEUSTADT, GERMANY, FEDERAL REPUBLIC OF
PI US 2003187001 A1 20031002
AI US 1999-399083 A1 19990917 (9)
RLI Continuation-in-part of Ser. No. US 1998-42702, filed on 17 Mar 1998, GRANTED, Pat. No. US 6001839
PRAI US 1998-100954P 19980918 (60)
DT Utility
FS APPLICATION
LN.CNT 5686
INCL INCLM: 514/265.100
INCLS: 544/280.000

NCL NCLM: 514/265.100
NCLS: 544/280.000
IC [7]
ICM: A61K031-519
ICS: C07D487-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 2 USPATFULL on STN
AN 1999:163694 USPATFULL
TI Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors
IN **Calderwood, David J.**, Nottingham, United Kingdom
Johnston, David N., Nottingham, United Kingdom
Rafferty, Paul, Nottingham, United Kingdom
Twigger, Helen L., Nottingham, United Kingdom
Munschauer, Rainer, Shrewsbury, MA, United States
Arnold, Lee, Westborough, MA, United States
PA BASF Aktiengesellschaft, Rheinland-Pfalz, Germany, Federal Republic of
(non-U.S. corporation)
PI US 6001839 19991214 <--
AI US 1998-42702 19980317 (9)
PRAI US 1997-40836P 19970319 (60)
DT Utility
FS Granted
LN.CNT 2239
INCL INCLM: 514/258.000
INCLS: 544/280.000
NCL NCLM: 514/265.100
NCLS: 544/280.000
IC [6]
ICM: C07D487-04
ICS: A61K031-505
EXF 544/280; 514/258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ind tot

L8 ANSWER 1 OF 2 USPATFULL on STN
INCL INCLM: 514/265.100
INCLS: 544/280.000
NCL NCLM: 514/265.100
NCLS: 544/280.000
IC [7]
ICM: A61K031-519
ICS: C07D487-02

CHEMICAL ABSTRACTS INDEXING COPYRIGHT 2004 ACS on STN

	PATENT	KIND	DATE
OS CA 132:251159	WO 0017202	A1	20000330
CA 139:292260 *	US 20030187001	A1	20031002

* CA Indexing for this record included
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
ST pyrrolopyrimidinamine prepn protein kinase inhibitor; anticancer
antiproliferative antirheumatic antiinflammatory immunomodulator
pyrrolopyrimidinamine prepn
IT Intestine, disease
(Crohn's, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines
for inhibiting protein kinase activity)
IT Sarcoma
(Kaposi's, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines
for inhibiting protein kinase activity)

IT Bone, disease
(Paget's, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Tyrosine kinase receptors
(Tie-2; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)
IT B cell (lymphocyte)
(activation; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity which is involved in B cell activation)
IT T cell (lymphocyte)
(activation; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity which is involved in T cell activation)
IT Monocyte
(activation; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity which is involved in monocyte activation)
IT Antiarteriosclerotics
(antiatherosclerotics; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Artery
(carotid, treatment of carotid obstructive disease; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Lung, disease
(chronic obstructive, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Inflammation
(chronic, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Eye, disease
(conjunctivitis, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Mast cell
(degranulation; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity which is involved in mast cell degranulation)
IT Eye, disease
(diabetic retinopathy, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Brain, disease
Lung, disease
(edema, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Pleura, disease
(effusion, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Uterus, disease
(endometriosis, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Sarcoma
(fibrosarcoma, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Necrosis
(gangrene, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for treating cancer and hyperproliferative disorders)
IT Neuroglia, neoplasm
(glioblastoma, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Kidney, disease
(glomerulonephritis, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Capillary vessel, disease
(hereditary hemorrhagic telangiectasia, treatment of Osler-Weber-Rendu disease; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Ovary, disease
(hyperstimulation syndrome, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Intestine, disease
(inflammatory, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Reperfusion
(injury, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Diabetes mellitus
(insulin-dependent, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Eye, disease
(macula, degeneration, Stargardt's disease, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Vein, disease
(malformation, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Blood vessel, disease
(microangiopathy, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Vision
(myopia, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Ascites
(neoplasm, treatment of malignant ascites; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Hematopoietic precursor cell
(neoplasm, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Angiogenesis
(neovascularization, eye, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Eye, disease
(neovascularization, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Nerve, neoplasm
(neuroblastoma, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Blood vessel, disease
(occlusion, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Skin, disease
(pemphigoid, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Biological transport
(permeation, vascular; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity which affects angiogenesis, vascular permeability, immune responses or inflammation)
IT Kidney, disease
(polycystic, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Angiogenesis
Angiogenesis inhibitors
Anti-inflammatory agents
Antidiabetic agents

Antirheumatic agents
Antitumor agents
Antiulcer agents
Antiviral agents
Cardiovascular agents
Cytotoxic agents
Human
Immunomodulators
(preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT Insulin-like growth factor I receptors
(preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT Hepatocyte growth factor
(preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT Antiarthritics
Antiasthmatics
(preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Immunity
Inflammation
(preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity which affects angiogenesis, vascular permeability, immune responses or inflammation)

IT Cell activation
(preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity which is involved in T cell activation and B cell activation)

IT Anti-ischemic agents
(preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for treating cancer and hyperproliferative disorders)

IT Artery, disease
(restenosis, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Eye, disease
(retina, detachment, treatment of chronic retinal detachment; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Eye, neoplasm
(retinoblastoma, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Eye, disease
(retinopathy, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Myoma
(rhabdomyosarcoma, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Neoplasm
(solid, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Synovial membrane, disease
(synovitis, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Lupus erythematosus
(systemic, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Carcinoma
(teratocarcinoma, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Thyroid gland, disease
(thyroiditis, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Toxoplasma gondii
(toxoplasmosis from, treatment of infection by Herpes simplex, HIV, parapoxvirus, protozoa or toxoplasmosis; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Edema
(treatment of edema following burns, trauma, radiation, stroke, hypoxia or ischemia; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Human herpesvirus
Human immunodeficiency virus
Parapoxvirus
Protozoa
(treatment of infection by Herpes simplex, HIV, parapoxvirus, protozoa or toxoplasmosis; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Keratosis
(treatment of radial keratoma; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Ulcer
(treatment of ulcers caused by a bacterial or fungal infection, or Mooren ulcers; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Ascites
Asthma
Atherosclerosis
Cirrhosis
Exudate
Fibrosis
Glaucoma (disease)
Hodgkin's disease
Leukemia
Lyme disease
Lymphoma
Melanoma
Multiple myeloma
Multiple sclerosis
Osteoarthritis
Preeclampsia
Psoriasis
Rheumatoid arthritis
Sarcoidosis
Sarcoma
Sepsis
Transplant rejection
(treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Anemia (disease)
Ischemia
Necrosis
Wound
(treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for treating cancer and hyperproliferative disorders)
IT Eye, disease
Sickle cell anemia
(treatment; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)
IT Fibroblast growth factor receptors
(type 1; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)
IT Intestine, disease
(ulcerative colitis, treatment of ulcers which are symptom of ulcerative colitis; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)
IT Fertility

(use for decreasing fertility; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Eye, disease
(uveitis, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Infection
(viral, treatment of infection by Herpes simplex, HIV, parapoxyvirus, protozoa or toxoplasmosis; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Nervous system, neoplasm
(von Hippel-Lindau disease, treatment of; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for inhibiting protein kinase activity)

IT Platelet-derived growth factor receptors
(α; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT Platelet-derived growth factor receptors
(β; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT 262433-21-6P
(intermediate; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT 5455-13-0P 6358-77-6P 16133-25-8P, 3-Pyridinesulfonyl chloride
19056-40-7P 32939-32-5P 66715-65-9P, 2-Pyridinesulfonyl chloride
118757-04-3P 123148-78-7P 159451-66-8P 213743-31-8P 213744-81-1P
213745-17-6P, 4-Chloro-7-cyclopentyl-5-iodo-7H-pyrrolo[2,3-d]pyrimidine
213745-20-1P 213745-23-4P 262433-01-2P 262433-02-3P 262433-03-4P
262433-04-5P 262433-05-6P 262433-06-7P 262433-07-8P 262433-08-9P
262433-09-0P 262433-10-3P 262433-11-4P 262433-12-5P 262433-13-6P
262433-14-7P 262433-15-8P 262433-16-9P 262433-17-0P 262433-18-1P
262433-19-2P 262433-20-5P 262433-22-7P 262433-23-8P 262433-24-9P
262433-25-0P 262433-26-1P 262433-27-2P 262433-28-3P 262433-29-4P
262433-30-7P 262433-31-8DP, resin-bound 262433-32-9P 262433-33-0P
262433-34-1P
(intermediate; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT 79079-06-4, Egfr tyrosine kinase 114051-78-4, Lck tyrosine kinase
137632-03-2, c-Met receptor tyrosine kinase 137632-06-5, Csk tyrosine kinase 140208-17-9, Lyn kinase 141349-87-3, Fyn kinase 141349-89-5, Src kinase 141349-91-9, Yes kinase 141350-03-0, Flt-1 vegf receptor tyrosine kinase 143375-65-9, Cdc2 kinase 144941-35-5, Blk kinase
148047-34-1, Zap70 tyrosine kinase 150977-45-0
(preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT 106096-92-8, Fgf-1 106096-93-9, Fgf-2 127464-60-2, Vascular endothelial growth factor 188417-84-7, Vegf-c 192662-83-2, Vascular endothelial growth factor b 193363-12-1, Vascular endothelial growth factor d 219563-02-7, Vascular endothelial growth factor e
(preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines for treating cancer and hyperproliferative disorders in combination with a pro-angiogenic growth factor)

IT 75-26-3, Isopropyl bromide 75-31-0, 2-Propylamine, reactions 90-41-5, 2-Aminobiphenyl 96-50-4, 2-Aminothiazole 98-09-9, Benzenesulfonyl chloride 100-55-0, 3-Pyridylcarbinol 100-59-4, Phenyl magnesium chloride 103-80-0, 2-Phenylethanoyl chloride 109-01-3, 1-Methylpiperazine 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 120-43-4, Ethyl 1-piperazinecarboxylate
123-75-1, Pyrrolidine, reactions 141-43-5, reactions 316-68-7
331-64-6, 2-Fluoro-4-methoxybenzaldehyde 367-24-8, 4-Bromo-2-fluoroaniline 367-86-2, 4-Fluoro-3-nitrobenzotrifluoride 394-47-8, 2-Fluorobenzonitrile 395-81-3, 5-Fluoro-2-nitrobenzaldehyde 400-74-8, 2-Fluoro-5-nitrobenzotrifluoride 403-42-9 445-02-3, 4-Bromo-2-(trifluoromethyl)aniline 445-27-2 446-07-1 446-22-0
446-29-7, 4'-Fluoro-2'-methylacetophenone 446-52-6,

2-Fluorobenzaldehyde 450-83-9, 4-Fluoro-2-methoxybenzaldehyde 453-72-5, 4-Fluoro-3-nitrophenyl methyl sulfone 459-57-4, 4-Fluorobenzaldehyde 459-73-4, Ethyl glycinate 501-53-1, Benzyl chloroformate 579-49-7, 4-Fluorophenyl 2-thienyl ketone 636-73-7, 3-Pyridinesulfonic acid 661-69-8, Hexamethylditin 700-35-6, 2'-Chloro-4'-fluoroacetophenone 700-84-5, 5-Fluoro-1-indanone 784-38-3 1072-97-5, 5-Bromo-2-pyridinamine 1194-02-1, 4-Fluorobenzonitrile 1514-16-5, 1-Fluoro-9-fluorenone 1939-99-7, Phenylmethanesulfonyl chloride 1979-36-8 2637-34-5, 2-Pyridinethiol 2646-91-5, 2,3-Difluorobenzaldehyde 2923-66-2, 3-Chloro-4-fluoroacetophenone 3173-56-6, Benzyl isocyanate 3680-69-1, 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine 4088-84-0, 2-Fluoro-5-(trifluoromethyl)benzonitrile 7693-46-1, p-Nitrophenyl chloroformate 10221-56-4 15862-72-3, Ethyl 2-piperidinecarboxylate 17417-09-3, 2-Fluoro-5-nitrobenzonitrile 20412-38-8, Neopentyl chloroformate 22190-33-6, 5-Bromoindoline 27996-87-8, 2-Fluoro-5-nitrobenzaldehyde 33696-00-3, 4-Bromo-1-methoxy-2-nitrobenzene 34328-61-5, 3-Chloro-4-fluorobenzaldehyde 38762-41-3, 4-Bromo-2-chloroaniline 39098-97-0, 2-(2-Thienyl)ethanoyl chloride 49584-26-1, 4-Cyanobenzenesulfonyl chloride 59557-91-4, 4-Bromo-2-methoxyaniline 60702-69-4, 2-Chloro-4-fluorobenzonitrile 61072-56-8, 4-Chloro-2-fluorobenzaldehyde 64248-62-0, 3,4-Difluorobenzonitrile 64248-64-2, 2,5-Difluorobenzonitrile 67515-59-7, 4-Fluoro-3-(trifluoromethyl)benzonitrile 67515-60-0, 4-Fluoro-3-(trifluoromethyl)benzaldehyde 69360-26-5, 2-Cyanobenzenesulfonyl chloride 71924-62-4, 6-Fluoroveratraldehyde 74457-86-6 77337-82-7, 1-Bromo-2-methoxy-4-nitrobenzene 79110-05-7, 2'-Fluoro-5'-nitroacetophenone 82652-17-3 87199-17-5 90176-80-0, 4-Fluoro-2-(trifluoromethyl)benzaldehyde 96994-73-9, 2-Dimethylamino-6-fluorobenzonitrile 101646-02-0, 3-Chloro-4-fluoro-5-nitrobenzotrifluoride 105728-90-3, 2-Fluoro-5-methoxybenzaldehyde 112641-20-0, 2-Fluoro-3-(trifluoromethyl)benzaldehyde 117482-84-5, 3-Chloro-4-fluorobenzonitrile 119584-74-6, 2-Fluoro-6-(2,2,2-trifluoroethoxy)benzonitrile 122023-29-4 127667-01-0, 2-Fluoro-5-methoxybenzonitrile 128843-61-8, 4-(4-Fluorobenzoyl)-1-methylpyrrole-2-aldehyde 146070-35-1, 2-Fluoro-3-(trifluoromethyl)benzonitrile 148901-51-3, 2-Fluoro-6-(1-pyrrolo)benzonitrile 148901-53-5, 3-Cyano-4-dimethylamino-2-fluorobenzaldehyde 174013-29-7 175204-08-7, 2-Fluoro-6-(4-methylphenoxy)benzonitrile 175204-11-2, 2-Fluoro-6-(4-methylphenylthio)benzonitrile 177211-26-6, 4-Chloro-2-fluoro-5-methylacetophenone 196712-50-2, 3-Chlorocyclohexyl chloroformate 202664-53-7 207853-63-2 207974-18-3 208173-16-4 208173-21-1 213744-10-6 213744-43-5 213744-78-6 213744-90-2 239107-27-8 262433-35-2 262433-36-3, 2-Fluoro-6-(2-pyridylthio)benzonitrile 262433-37-4, 2-Fluoro-6-(methoxycarbonylmethylthio)benzonitrile 262433-38-5, 3-Phenyl-7-fluoroindan-1-one 262433-39-6 262433-40-9, 2-Fluoro-6-(4-carbamoylpiperidin-1-yl)benzonitrile 262433-41-0 262433-42-1 262433-43-2 262433-44-3, 2-Fluoro-6-(4-cyanopiperidin-1-yl)benzonitrile 262433-45-4 262433-47-6 262433-48-7 262433-49-8, 2-Fluoro-6-(3-methoxypropylamino)benzonitrile 262433-50-1 262433-51-2 262433-52-3 262433-53-4
(reactant; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT 262430-36-4P 262430-37-5P 262430-38-6P 262430-39-7P 262430-40-0P 262430-41-1P 262430-42-2P 262430-43-3P 262430-44-4P 262430-45-5P 262430-46-6P 262430-47-7P 262430-48-8P 262430-49-9P 262430-50-2P 262430-51-3P 262430-52-4P 262430-53-5P 262430-54-6P 262430-55-7P 262430-56-8P 262430-57-9P 262430-58-0P 262430-59-1P 262430-60-4P 262430-61-5P 262430-62-6P 262430-63-7P 262430-64-8P 262430-66-0P 262430-93-3P 262431-64-1P
(target compound; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT 213743-94-3P 262430-03-5P 262430-04-6P 262430-05-7P 262430-06-8P

262430-07-9P 262430-08-0P 262430-09-1P 262430-10-4P 262430-11-5P
262430-12-6P 262430-13-7P 262430-14-8P 262430-15-9P 262430-16-0P
262430-17-1P 262430-18-2P 262430-19-3P 262430-20-6P 262430-21-7P
262430-22-8P 262430-23-9P 262430-24-0P 262430-25-1P 262430-26-2P
262430-27-3P 262430-28-4P 262430-29-5P 262430-30-8P 262430-31-9P
262430-32-0P 262430-33-1P 262430-34-2P 262430-35-3P 262430-65-9P
262430-67-1P 262430-68-2P 262430-69-3P 262430-70-6P 262430-71-7P
262430-72-8P 262430-73-9P 262430-74-0P 262430-75-1P 262430-76-2P
262430-77-3P 262430-78-4P 262430-80-8P 262430-81-9P 262430-82-0P
262430-83-1P 262430-84-2P 262430-85-3P 262430-86-4P 262430-87-5P
262430-88-6P 262430-89-7P 262430-90-0P 262430-91-1P 262430-92-2P
262430-94-4P 262430-95-5P 262430-96-6P 262430-97-7P 262430-98-8P
262430-99-9P 262431-00-5P 262431-01-6P 262431-02-7P 262431-03-8P
262431-04-9P 262431-05-0P 262431-06-1P 262431-07-2P 262431-08-3P
262431-09-4P 262431-10-7P 262431-11-8P 262431-12-9P 262431-13-0P
262431-14-1P 262431-15-2P 262431-16-3P 262431-17-4P 262431-18-5P
262431-19-6P 262431-20-9P 262431-21-0P 262431-22-1P 262431-23-2P
262431-24-3P 262431-25-4P 262431-26-5P 262431-27-6P 262431-28-7P
262431-29-8P 262431-30-1P 262431-31-2P 262431-32-3P 262431-33-4P
262431-34-5P 262431-35-6P 262431-36-7P 262431-37-8P 262431-38-9P
262431-39-0P 262431-40-3P 262431-41-4P 262431-42-5P 262431-43-6P
262431-44-7P 262431-45-8P 262431-46-9P 262431-47-0P 262431-48-1P
262431-49-2P 262431-50-5P 262431-51-6P 262431-52-7P 262431-53-8P
262431-54-9P 262431-55-0P 262431-56-1P 262431-57-2P 262431-58-3P
262431-59-4P 262431-60-7P 262431-61-8P 262431-62-9P 262431-63-0P
262431-65-2P 262431-66-3P 262431-67-4P 262431-68-5P 262431-69-6P
262431-70-9P 262431-71-0P 262431-72-1P 262431-73-2P 262431-74-3P
262431-75-4P 262431-76-5P 262431-77-6P 262431-78-7P 262431-79-8P
262431-80-1P 262431-81-2P 262431-82-3P 262431-83-4P 262431-84-5P
262431-85-6P 262431-86-7P 262431-87-8P 262431-88-9P 262431-89-0P
262431-90-3P 262431-91-4P 262431-92-5P 262431-93-6P 262431-94-7P
262431-95-8P 262431-96-9P 262431-98-1P 262432-00-8P 262432-01-9P
262432-02-0P 262432-03-1P 262432-04-2P 262432-05-3P 262432-06-4P
262432-07-5P 262432-08-6P 262432-09-7P 262432-10-0P 262432-11-1P
262432-12-2P 262432-13-3P 262432-14-4P 262432-15-5P 262432-16-6P
262432-17-7P 262432-18-8P 262432-19-9P 262432-20-2P 262432-21-3P
262432-22-4P 262432-23-5P 262432-24-6P 262432-25-7P 262432-26-8P
262432-27-9P 262432-28-0P 262432-29-1P 262432-30-4P 262432-31-5P
262432-32-6P 262432-33-7P 262432-34-8P 262432-35-9P 262432-36-0P
262432-37-1P 262432-38-2P 262432-39-3P 262432-40-6P 262432-41-7P
262432-42-8P 262432-43-9P 262432-44-0P 262432-45-1P 262432-46-2P
262432-47-3P 262432-48-4P 262432-49-5P 262432-50-8P 262432-51-9P
262432-52-0P 262432-53-1P 262432-54-2P 262432-55-3P 262432-56-4P
262432-57-5P 262432-58-6P 262432-59-7P 262432-60-0P 262432-61-1P
262432-62-2P 262432-63-3P 262432-65-5P 262432-66-6P 262432-67-7P
262432-68-8P 262432-69-9P 262432-70-2P 262432-71-3P 262432-72-4P
(target compound; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT 262432-73-5P 262432-74-6P 262432-75-7P 262432-76-8P 262432-77-9P
262432-78-0P 262432-79-1P 262432-80-4P 262432-81-5P 262432-82-6P
262432-83-7P 262432-84-8P 262432-85-9P 262432-86-0P 262432-87-1P
262432-88-2P 262432-89-3P 262432-90-6P 262432-91-7P 262432-92-8P
262432-93-9P 262432-94-0P 262432-95-1P 262432-96-2P 262432-97-3P
262432-98-4P 262432-99-5P 262433-00-1P
(target compound; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

L8 ANSWER 2 OF 2 USPATFULL on STN
INCL INCLM: 514/258.000
INCLS: 544/280.000
NCL NCLM: 514/265.100
NCLS: 544/280.000
IC [6]
ICM: C07D487-04

ICS: A61K031-505
EXF 544/280; 514/258
ARTU 161

CHEMICAL ABSTRACTS INDEXING COPYRIGHT 2004 ACS on STN

		PATENT	KIND	DATE
OS	CA 132:251159 * WO	0017202	A1	20000330
	CA 139:292260 US	20030187001	A1	20031002

* CA Indexing for this record included

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

ST pyrrolopyrimidinamine prepn protein kinase inhibitor; anticancer antiproliferative antirheumatoid antiinflammatory immunomodulator pyrrolopyrimidinamine prepn

IT Tyrosine kinase receptors
(Tie, TIE-2; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT Vascular endothelial growth factor receptors
(gene KDR; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT Phospholipoproteins
(p62c-yes; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT Angiogenesis inhibitors
Anti-inflammatory agents
Antidiabetic agents
Antirheumatic agents
Antitumor agents
Antiulcer agents
Antiviral agents
Cardiovascular agents
Cytotoxic agents
Immunomodulators
(preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT Hepatocyte growth factor receptors
Insulin-like growth factor I receptors
(preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT Hepatocyte growth factor
(preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT Proliferation inhibition
(proliferation inhibitors; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT Eye, disease
Sickle cell anemia
(treatment; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT Fibroblast growth factor receptors
(type 1; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT Platelet-derived growth factor receptors
(α; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT Platelet-derived growth factor receptors
(β; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT 262433-21-6P
(intermediate; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT 5455-13-0P 6358-77-6P 16133-25-8P, 3-Pyridinesulfonyl chloride

19056-40-7P 32939-32-5P 66715-65-9P, 2-Pyridinesulfonyl chloride
118757-04-3P 123148-78-7P 159451-66-8P 213743-31-8P 213744-81-1P
213745-17-6P, 4-Chloro-7-cyclopentyl-5-iodo-7H-pyrrolo[2,3-d]pyrimidine
213745-20-1P 213745-23-4P 262433-01-2P 262433-02-3P 262433-03-4P
262433-04-5P 262433-05-6P 262433-06-7P 262433-07-8P 262433-08-9P
262433-09-0P 262433-10-3P 262433-11-4P 262433-12-5P 262433-13-6P
262433-14-7P 262433-15-8P 262433-16-9P 262433-17-0P 262433-18-1P
262433-19-2P 262433-20-5P 262433-22-7P 262433-23-8P 262433-24-9P
262433-25-0P 262433-26-1P 262433-27-2P 262433-28-3P 262433-29-4P
262433-30-7P 262433-31-8DP, resin-bound 262433-32-9P 262433-33-0P
262433-34-1P
(intermediate; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT 75-26-3, Isopropyl bromide 75-31-0, 2-Propylamine, reactions 90-41-5, 2-Aminobiphenyl 96-50-4, 2-Aminothiazole 98-09-9, Benzenesulfonyl chloride 100-55-0, 3-Pyridylcarbinol 100-59-4, Phenyl magnesium chloride 103-80-0, 2-Phenylethanoyl chloride 109-01-3, 1-Methylpiperazine 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 120-43-4, Ethyl 1-piperazinecarboxylate 123-75-1, Pyrrolidine, reactions 141-43-5, reactions 316-68-7 331-64-6, 2-Fluoro-4-methoxybenzaldehyde 367-24-8, 4-Bromo-2-fluoroaniline 367-86-2, 4-Fluoro-3-nitrobenzotrifluoride 394-47-8, 2-Fluorobenzonitrile 395-81-3, 5-Fluoro-2-nitrobenzaldehyde 400-74-8, 2-Fluoro-5-nitrobenzotrifluoride 403-42-9 445-02-3, 4-Bromo-2-(trifluoromethyl)aniline 445-27-2 446-07-1 446-22-0 446-29-7, 4'-Fluoro-2'-methylacetophenone 446-52-6, 2-Fluorobenzaldehyde 450-83-9, 4-Fluoro-2-methoxybenzaldehyde 453-72-5, 4-Fluoro-3-nitrophenyl methyl sulfone 459-57-4, 4-Fluorobenzaldehyde 459-73-4, Ethyl glycinate 501-53-1, Benzyl chloroformate 579-49-7, 4-Fluorophenyl 2-thienyl ketone 636-73-7, 3-Pyridinesulfonic acid 661-69-8, Hexamethylditin 700-35-6, 2'-Chloro-4'-fluoroacetophenone 700-84-5, 5-Fluoro-1-indanone 784-38-3 1072-97-5, 5-Bromo-2-pyridinamine 1194-02-1, 4-Fluorobenzonitrile 1514-16-5, 1-Fluoro-9-fluorenone 1939-99-7, Phenylmethanesulfonyl chloride 1979-36-8 2637-34-5, 2-Pyridinethiol 2646-91-5, 2,3-Difluorobenzaldehyde 2923-66-2, 3-Chloro-4-fluoroacetophenone 3173-56-6, Benzyl isocyanate 3680-69-1, 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine 4088-84-0, 2-Fluoro-5-(trifluoromethyl)benzonitrile 7693-46-1, p-Nitrophenyl chloroformate 10221-56-4 15862-72-3, Ethyl 2-piperidinecarboxylate 17417-09-3, 2-Fluoro-5-nitrobenzonitrile 20412-38-8, Neopentyl chloroformate 22190-33-6, 5-Bromoindoline 27996-87-8, 2-Fluoro-5-nitrobenzaldehyde 33696-00-3, 4-Bromo-1-methoxy-2-nitrobenzene 34328-61-5, 3-Chloro-4-fluorobenzaldehyde 38762-41-3, 4-Bromo-2-chloroaniline 39098-97-0, 2-(2-Thienyl)ethanoyl chloride 49584-26-1, 4-Cyanobenzenesulfonyl chloride 59557-91-4, 4-Bromo-2-methoxyaniline 60702-69-4, 2-Chloro-4-fluorobenzonitrile 61072-56-8, 4-Chloro-2-fluorobenzaldehyde 64248-62-0, 3,4-Difluorobenzonitrile 64248-64-2, 2,5-Difluorobenzonitrile 67515-59-7, 4-Fluoro-3-(trifluoromethyl)benzonitrile 67515-60-0, 4-Fluoro-3-(trifluoromethyl)benzaldehyde 69360-26-5, 2-Cyanobenzenesulfonyl chloride 71924-62-4, 6-Fluoroveratraldehyde 74457-86-6 77337-82-7, 1-Bromo-2-methoxy-4-nitrobenzene 79110-05-7, 2'-Fluoro-5'-nitroacetophenone 82652-17-3 87199-17-5 90176-80-0, 4-Fluoro-2-(trifluoromethyl)benzaldehyde 96994-73-9, 2-Dimethylamino-6-fluorobenzonitrile 101646-02-0, 3-Chloro-4-fluoro-5-nitrobenzotrifluoride 105728-90-3, 2-Fluoro-5-methoxybenzaldehyde 112641-20-0, 2-Fluoro-3-(trifluoromethyl)benzaldehyde 117482-84-5, 3-Chloro-4-fluorobenzonitrile 119584-74-6, 2-Fluoro-6-(2,2,2-trifluoroethoxy)benzonitrile 122023-29-4 127667-01-0, 2-Fluoro-5-methoxybenzonitrile 128843-61-8, 4-(4-Fluorobenzoyl)-1-methylpyrrole-2-aldehyde 146070-35-1, 2-Fluoro-3-(trifluoromethyl)benzonitrile 148901-51-3, 2-Fluoro-6-(1-pyrrolo)benzonitrile 148901-53-5, 3-Cyano-4-dimethylamino-2-

fluorobenzaldehyde 174013-29-7 175204-08-7, 2-Fluoro-6-(4-methylphenoxy)benzonitrile 175204-11-2, 2-Fluoro-6-(4-methylphenylthio)benzonitrile 177211-26-6, 4-Chloro-2-fluoro-5-methylacetophenone 196712-50-2, 3-Chlorocyclohexyl chloroformate 202664-53-7 207853-63-2 207974-18-3 208173-16-4 208173-21-1 213744-10-6 213744-43-5 213744-78-6 213744-90-2 239107-27-8 262433-35-2 262433-36-3, 2-Fluoro-6-(2-pyridylthio)benzonitrile 262433-37-4, 2-Fluoro-6-(methoxycarbonylmethylthio)benzonitrile 262433-38-5, 3-Phenyl-7-fluoroindan-1-one 262433-39-6 262433-40-9, 2-Fluoro-6-(4-carbamoylpiperidin-1-yl)benzonitrile 262433-41-0 262433-42-1 262433-43-2 262433-44-3, 2-Fluoro-6-(4-cyanopiperidin-1-yl)benzonitrile 262433-45-4 262433-47-6 262433-48-7 262433-49-8, 2-Fluoro-6-(3-methoxypropylamino)benzonitrile 262433-50-1 262433-51-2 262433-52-3 262433-53-4
(reactant; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT 262430-36-4P 262430-37-5P 262430-38-6P 262430-39-7P 262430-40-0P 262430-41-1P 262430-42-2P 262430-43-3P 262430-44-4P 262430-45-5P 262430-46-6P 262430-47-7P 262430-48-8P 262430-49-9P 262430-50-2P 262430-51-3P 262430-52-4P 262430-53-5P 262430-54-6P 262430-55-7P 262430-56-8P 262430-57-9P 262430-58-0P 262430-59-1P 262430-60-4P 262430-61-5P 262430-62-6P 262430-63-7P 262430-64-8P 262430-66-0P 262430-93-3P 262431-64-1P
(target compound; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT 213743-94-3P 262430-03-5P 262430-04-6P 262430-05-7P 262430-06-8P 262430-07-9P 262430-08-0P 262430-09-1P 262430-10-4P 262430-11-5P 262430-12-6P 262430-13-7P 262430-14-8P 262430-15-9P 262430-16-0P 262430-17-1P 262430-18-2P 262430-19-3P 262430-20-6P 262430-21-7P 262430-22-8P 262430-23-9P 262430-24-0P 262430-25-1P 262430-26-2P 262430-27-3P 262430-28-4P 262430-29-5P 262430-30-8P 262430-31-9P 262430-32-0P 262430-33-1P 262430-34-2P 262430-35-3P 262430-65-9P 262430-67-1P 262430-68-2P 262430-69-3P 262430-70-6P 262430-71-7P 262430-72-8P 262430-73-9P 262430-74-0P 262430-75-1P 262430-76-2P 262430-77-3P 262430-78-4P 262430-80-8P 262430-81-9P 262430-82-0P 262430-83-1P 262430-84-2P 262430-85-3P 262430-86-4P 262430-87-5P 262430-88-6P 262430-89-7P 262430-90-0P 262430-91-1P 262430-92-2P 262430-94-4P 262430-95-5P 262430-96-6P 262430-97-7P 262430-98-8P 262430-99-9P 262431-00-5P 262431-01-6P 262431-02-7P 262431-03-8P 262431-04-9P 262431-05-0P 262431-06-1P 262431-07-2P 262431-08-3P 262431-09-4P 262431-10-7P 262431-11-8P 262431-12-9P 262431-13-0P 262431-14-1P 262431-15-2P 262431-16-3P 262431-17-4P 262431-18-5P 262431-19-6P 262431-20-9P 262431-21-0P 262431-22-1P 262431-23-2P 262431-24-3P 262431-25-4P 262431-26-5P 262431-27-6P 262431-28-7P 262431-29-8P 262431-30-1P 262431-31-2P 262431-32-3P 262431-33-4P 262431-34-5P 262431-35-6P 262431-36-7P 262431-37-8P 262431-38-9P 262431-39-0P 262431-40-3P 262431-41-4P 262431-42-5P 262431-43-6P 262431-44-7P 262431-45-8P 262431-46-9P 262431-47-0P 262431-48-1P 262431-49-2P 262431-50-5P 262431-51-6P 262431-52-7P 262431-53-8P 262431-54-9P 262431-55-0P 262431-56-1P 262431-57-2P 262431-58-3P 262431-59-4P 262431-60-7P 262431-61-8P 262431-62-9P 262431-63-0P 262431-65-2P 262431-66-3P 262431-67-4P 262431-68-5P 262431-69-6P 262431-70-9P 262431-71-0P 262431-72-1P 262431-73-2P 262431-74-3P 262431-75-4P 262431-76-5P 262431-77-6P 262431-78-7P 262431-79-8P 262431-80-1P 262431-81-2P 262431-82-3P 262431-83-4P 262431-84-5P 262431-85-6P 262431-86-7P 262431-87-8P 262431-88-9P 262431-89-0P 262431-90-3P 262431-91-4P 262431-92-5P 262431-93-6P 262431-94-7P 262431-95-8P 262431-96-9P 262431-98-1P 262432-00-8P 262432-01-9P 262432-02-0P 262432-03-1P 262432-04-2P 262432-05-3P 262432-06-4P 262432-07-5P 262432-08-6P 262432-09-7P 262432-10-0P 262432-11-1P 262432-12-2P 262432-13-3P 262432-14-4P 262432-15-5P 262432-16-6P 262432-17-7P 262432-18-8P 262432-19-9P 262432-20-2P 262432-21-3P 262432-22-4P 262432-23-5P 262432-24-6P 262432-25-7P 262432-26-8P 262432-27-9P 262432-28-0P 262432-29-1P 262432-30-4P 262432-31-5P

262432-32-6P 262432-33-7P 262432-34-8P 262432-35-9P 262432-36-0P
262432-37-1P 262432-38-2P 262432-39-3P 262432-40-6P 262432-41-7P
262432-42-8P 262432-43-9P 262432-44-0P 262432-45-1P 262432-46-2P
262432-47-3P 262432-48-4P 262432-49-5P 262432-50-8P 262432-51-9P
262432-52-0P 262432-53-1P 262432-54-2P 262432-55-3P 262432-56-4P
262432-57-5P 262432-58-6P 262432-59-7P 262432-60-0P 262432-61-1P
262432-62-2P 262432-63-3P 262432-65-5P 262432-66-6P 262432-67-7P
262432-68-8P 262432-69-9P 262432-70-2P 262432-71-3P
(target compound; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

IT 262432-72-4P 262432-73-5P 262432-74-6P 262432-75-7P 262432-76-8P
262432-77-9P 262432-78-0P 262432-79-1P 262432-80-4P 262432-81-5P
262432-82-6P 262432-83-7P 262432-84-8P 262432-85-9P 262432-86-0P
262432-87-1P 262432-88-2P 262432-89-3P 262432-90-6P 262432-91-7P
262432-92-8P 262432-93-9P 262432-94-0P 262432-95-1P 262432-96-2P
262432-97-3P 262432-98-4P 262432-99-5P 262433-00-1P
(target compound; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

```
=> s l8 and (262430-74-0 or 262430-83-1 or 262431-15-2 or 262431-28-7 or
262431-65-2 or 262433-34-1 or 213743-31-8)/rn
             2 262430-74-0/RN
             2 262430-83-1/RN
             2 262431-15-2/RN
             2 262431-28-7/RN
             2 262431-65-2/RN
             2 262433-34-1/RN
             2 213743-31-8/RN
L9           2 L8 AND (262430-74-0 OR 262430-83-1 OR 262431-15-2 OR 262431-28-7
               OR 262431-65-2 OR 262433-34-1 OR 213743-31-8)/RN
```

```
=> d hitrn tot

L9   ANSWER 1 OF 2  USPATFULL on STN
IT   213743-31-8P 262433-34-1P
       (intermediate; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein
       kinase inhibitors)
IT   262430-74-0P 262430-83-1P 262431-15-2P
     262431-28-7P 262431-65-2P
       (target compound; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as
       protein kinase inhibitors)

L9   ANSWER 2 OF 2  USPATFULL on STN
IT   213743-31-8P 262433-34-1P
       (intermediate; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein
       kinase inhibitors)
IT   262430-74-0P 262430-83-1P 262431-15-2P
     262431-28-7P 262431-65-2P
       (target compound; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as
       protein kinase inhibitors)
```

```
=> fil reg
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              26.22      51.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -1.47

FILE 'REGISTRY' ENTERED AT 11:37:00 ON 02 AUG 2004
```

```
=> s (262430-74-0 or 262430-83-1 or 262431-15-2 or 262431-28-7 or 262431-65-2 or
262433-34-1 or 213743-31-8)/rn
             1 262430-74-0/RN
             1 262430-83-1/RN
             1 262431-15-2/RN
             1 262431-28-7/RN
             1 262431-65-2/RN
             1 262433-34-1/RN
             1 213743-31-8/RN
L10          7 (262430-74-0 OR 262430-83-1 OR 262431-15-2 OR 262431-28-7 OR
               262431-65-2 OR 262433-34-1 OR 213743-31-8)/RN

=> d tot

L10  ANSWER 1 OF 7  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   262433-34-1  REGISTRY
CN   7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-bromo-7-cyclopentyl-5-(4-
     phenoxyphenyl)- (9CI)  (CA INDEX NAME)
FS   3D CONCORD
MF   C23 H21 Br N4 O
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA  CAplus document type:  Journal; Patent
RL.P   Roles from patents:  PREP (Preparation); RACT (Reactant or reagent)
RL.NP  Roles from non-patents:  BIOL (Biological study); PREP (Preparation);
       PROC (Process); RACT (Reactant or reagent); USES (Uses)
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             3 REFERENCES IN FILE CA (1907 TO DATE)
             3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L10  ANSWER 2 OF 7  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   262431-65-2  REGISTRY
CN   7H-Pyrrolo[2,3-d]pyrimidine-6-methanamine, 4-amino-7-cyclopentyl-5-(4-
     phenoxyphenyl)- (9CI)  (CA INDEX NAME)
FS   3D CONCORD
MF   C24 H25 N5 O
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA  CAplus document type:  Journal; Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); USES
       (Uses)
RL.NP  Roles from non-patents:  BIOL (Biological study); PREP (Preparation);
       PROC (Process); RACT (Reactant or reagent); USES (Uses)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L10 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN **262431-28-7** REGISTRY
CN Benzenemethanol, 2-[4-[4-amino-7-(1-methylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenoxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H22 N4 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L10 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN **262431-15-2** REGISTRY
CN Benzenemethanol, 4-[4-[4-amino-7-(1-methylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenoxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H22 N4 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L10 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN **262430-83-1** REGISTRY
CN Benzonitrile, 2-[4-[4-amino-7-(1-methylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenoxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H19 N5 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L10 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN **262430-74-0** REGISTRY
CN Benzonitrile, 4-[4-[4-amino-7-(1-methylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenoxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H19 N5 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L10 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN **213743-31-8** REGISTRY
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-cyclopentyl-5-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H22 N4 O
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 213743-29-4/rn
L1 1 213743-29-4/RN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **213743-29-4** REGISTRY
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(1,1-dimethylethyl)-5-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H22 N4 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 213743-30-7/rn
L2 1 213743-30-7/RN

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **213743-30-7** REGISTRY
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(1-methylethyl)-5-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H20 N4 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s 213743-38-5/rn
L3            1 213743-38-5/RN

=> d

L3   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   213743-38-5  REGISTRY
CN   7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(1,1-dimethylethyl)-5-[4-(4-
     methoxyphenoxy)phenyl]- (9CI)  (CA INDEX NAME)
FS   3D CONCORD
MF   C23 H24 N4 O2
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER
DT.CA  CAplus document type:  Journal; Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); RACT
       (Reactant or reagent); USES (Uses)
RL.NP  Roles from non-patents:  BIOL (Biological study); PREP (Preparation);
       PROC (Process); RACT (Reactant or reagent); USES (Uses)
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

              2 REFERENCES IN FILE CA (1907 TO DATE)
              2 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s 213743-46-5/rn
L4            1 213743-46-5/RN

=> d

L4   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   213743-46-5  REGISTRY
CN   7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[4-(2-aminophenoxy)phenyl]-7-(1-
     methylethyl)- (9CI)  (CA INDEX NAME)
FS   3D CONCORD
MF   C21 H21 N5 O
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER
DT.CA  CAplus document type:  Journal; Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); RACT
       (Reactant or reagent); USES (Uses)
RL.NP  Roles from non-patents:  BIOL (Biological study); PREP (Preparation);
       PROC (Process); RACT (Reactant or reagent); USES (Uses)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s 213743-50-1/rn
L5            1 213743-50-1/RN

=> d

L5   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   213743-50-1  REGISTRY
CN   7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[4-(4-aminophenoxy)phenyl]-7-(1,1-
     dimethylethyl)- (9CI)  (CA INDEX NAME)
FS   3D CONCORD
MF   C22 H23 N5 O
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER
DT.CA  CAplus document type:  Journal; Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); USES
       (Uses)
RL.NP  Roles from non-patents:  BIOL (Biological study); PREP (Preparation);
       PROC (Process); RACT (Reactant or reagent); USES (Uses)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s 213743-54-5/rn
L6            1 213743-54-5/RN

=> d

L6   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   213743-54-5  REGISTRY
CN   7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[4-(3-aminophenoxy)phenyl]-7-(1,1-
     dimethylethyl)- (9CI)  (CA INDEX NAME)
```